Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

UCLA researchers found that two proteins doctors use to check for heart damage can also predict cancer years before symptoms ...

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

As such, the 2nd Peptide Formulation & Delivery Innovation Summit (June 24 - 26, 2025 | Boston, MA) returns as the only industry-specific event helping you catapult peptide-based drugs through ...

Plasma procollagen type III aminoterminal peptide (a biochemical marker of fibrosis) in the carotid sinus was significantly lower in the torsemide group than in the furosemide group (0.52 vs 0.67 ...